

RECEIVED

MAR 20 2003

Attorney Docket No.: 5686.200-US

PATENT

TECH CENTER 1600/2900

16249
3/28/03
C. S. J. E.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Teng et al.

Application No.: 09/483,504

Group Art Unit: 1624

Filed: January 14, 2000

Examiner: To be assigned

Confirmation No. 8481

For: Non-Peptide GLP-1 Agonists

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
Washington, DC 20231

Sir:

This paper is being filed in response to the Office Action mailed February 11, 2003 that made restriction and election of species requirements. Applicants were requested to elect one of three designated groups, I-III, and a species within the elected group, for continued prosecution.


In response to these requirements, Applicants hereby elect the invention of Group III,

(Class 1.4.6.17.21.26.20.26.27.52.53.65 and 66) and the invention of Group I, 102

The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: March 11, 2003



Richard W. Bork, Reg. No. 36,459

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West

Princeton, NJ 08540

(609) 987-5800



02650

RECEIVED

MAR 20 2003

PATENT

Attorney Docket No.: 5686.200-US

CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Teng et al.

Serial No.: 09/483,504

Group Art Unit: 1614

Filed: January 14, 2000

Examiner: To be assigned

For: Non-Peptide GLP-1 Agonists

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
Washington, DC 20231

on March 11, 2003.

Rashida Haji

(name of person mailing paper)